WeLeader Biomedical Co., Ltd. (7713) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of WeLeader Biomedical Co., Ltd. stock TWD 55.88, price TWD 70.60, that is 20.8% below the price, quality 48 out of 100. Rating: overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
34‑month range 49.07 TWD – 77.14 TWD · fair‑value band 31.01 TWD – 87.75 TWD · the 70.60 TWD price screens above the 55.88 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow WeLeader Biomedical Co. in your weekly email
Every Wednesday you see whether WeLeader Biomedical Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
WeLeader Biomedical Co., Ltd. operates as an agent and distributor of in vitro diagnostic products. It offers a range of medical testing systems, such as serum biochemistry integration platform, clinical care, and medical information integration system.
Show moreShow less
The company also provides blood gas electrolyte analyzers, urine analyzers, integrated fully automatic biochemical analyzers, fully automatic electronic luminescence immunoassay products, fully automatic modular biochemical immune assay products, TTA automated pre-processing products, POCT central laboratory products, and CCM fully automated track processing products.
It serves research institutions, schools, hospitals, laboratories, and hospitals. The company was founded in 1992 and is headquartered in Kaohsiung, Taiwan.
Stock analysis
WeLeader Biomedical Co., Ltd. (7713) currently trades at 70.60 TWD, while our model-based Fair Value estimate is 55.88 TWD, 21% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 96.37 TWD per share, and 9 of the 26 models we run sit above the 70.60 TWD price.
Bear case: the Asset-Based group reads lowest at 18.56 TWD, and 17 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: 31.01 TWD (bear) to 87.75 TWD (bull), the price of 70.60 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
WeLeader Biomedical Co., Ltd. reported revenue of 1.1B TWD in FY2025 versus 841M TWD in FY2021, a compound +7.2%/yr. Reported net income was 209M TWD in FY2025, compounding +18.5%/yr from FY2021.
Key figures
Market cap 3.2B TWD (≈ $97.9M) Micro · P/E ratio 14.0 · P/S ratio 2.66 · EPS (TTM) 5.05 TWD · Dividend yield 5.8% · Net margin 20.6% · Return on equity 21.8% · Return on assets (EBIT) 12.0% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 77 out of 100 (low confidence).
What moves the price
The share trades about 6% below its 52-week high and 8% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 9% fair-value upside, at −21%, 7713 screens richer than that median.
Fair Value models
Bear31.01 TWDFair Value 55.88 TWDBull87.75 TWD
Price 70.60 TWD · Downside -20.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.8173 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.57/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+11.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.3%
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+18.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+12.5%
Dividend (yield on the price)5.8%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 24%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+25.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +23.6% a year for the price.
Compare WeLeader Biomedical Co., Ltd. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 399 stocks
Beats the industry median on 10/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score48 · Above median
Fair Value upside−20.8% · Below median
Profitability
Return on equity (12 months)21.8% · Top 25%
Return on assets8.5% · Top 25%
Net margin (12 months)20.6% · Top 25%
Operating margin (12 months)27.0% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)24.2% · Top 25%
Dividend yield (12 months)5.8% · Top 25%
Balance sheet
Debt / equity0.39× · Highest 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/E (12 months)14.0× · Cheapest 25%
P/B2.55× · Pricier than median
P/S (12 months)2.66× · Cheaper than median
Price / free cash flow (fiscal year)32.3× · Pricier than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is WeLeader Biomedical Co., Ltd. (7713) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 55.88 TWD versus a price of 70.60 TWD, about 21% lower (overvalued).
What is the fair value of 7713?
Our model-based fair value for WeLeader Biomedical Co., Ltd. is 55.88 TWD (as of Nov 9, 2026), built from audited fundamentals. The current price: 70.60 TWD.
What is the quality score of 7713?
WeLeader Biomedical Co., Ltd. has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for WeLeader Biomedical Co., Ltd. (7713)?
Our model-based price target is the fair value of 55.88 TWD (as of Nov 9, 2026) from 26 valuation models. Cautious scenario 31.01 TWD, optimistic scenario 87.75 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the WeLeader Biomedical Co., Ltd. stock forecast for 2026?
Our models put fair value at 55.88 TWD, about 21% lower versus a price of 70.60 TWD (overvalued). Cautious scenario 31.01 TWD, optimistic scenario 87.75 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of WeLeader Biomedical Co., Ltd. (7713)?
WeLeader Biomedical Co., Ltd. reported trailing-twelve-month revenue of about 1.2B TWD (latest available figure, as of Nov 9, 2026).
Does WeLeader Biomedical Co., Ltd. pay a dividend?
WeLeader Biomedical Co., Ltd. currently shows a dividend yield of 5.81% relative to its recent price (as of Nov 9, 2026).
How much is the dividend of WeLeader Biomedical Co., Ltd. (7713) and when is the ex-dividend date?
WeLeader Biomedical Co., Ltd. pays a dividend of 4.10 TWD per share a year, a dividend yield of 5.8%. The last ex-dividend date was Mar 27, 2026. The payout ratio is 81.2% of earnings. Free cash flow covers the dividend 0.53 times. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What growth is priced into WeLeader Biomedical Co., Ltd. (7713)?
For today's price to be fair in a discounted-cash-flow model, WeLeader Biomedical Co., Ltd. would have to grow free cash flow by +25.5 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +7.2 % per year. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of 7713 use?
Our models discount WeLeader Biomedical Co., Ltd. at 11.8 %: a base by market capitalisation (micro), damped by beta 0.06, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For WeLeader Biomedical Co., Ltd. that is +25.5 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has WeLeader Biomedical Co., Ltd. (7713) delivered so far?
Over the past 4 years revenue at WeLeader Biomedical Co., Ltd. grew +7.2 % a year. The price currently implies free-cash-flow growth of +25.5 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of WeLeader Biomedical Co., Ltd. (7713) growing?
The median revenue growth in the sector is +1.7 % a year. That is the yardstick for the growth priced into WeLeader Biomedical Co., Ltd. (+25.5 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of WeLeader Biomedical Co., Ltd. (7713)?
The free-cash-flow yield on the price is 3.10 %: that much free cash flow WeLeader Biomedical Co., Ltd. produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of WeLeader Biomedical Co., Ltd. (7713)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For WeLeader Biomedical Co., Ltd. it is 55.88 TWD per share (as of Nov 9, 2026), against a price of 70.60 TWD. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is WeLeader Biomedical Co., Ltd. stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 7713 trades above its calculated fair value: price 70.60 TWD, fair value 55.88 TWD, a gap of about −21% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 7713?
No. The price is what the market pays today (70.60 TWD); the fair value is what the company's own numbers justify (55.88 TWD). For WeLeader Biomedical Co., Ltd. the two are 14.72 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is WeLeader Biomedical Co., Ltd. worth?
The market values WeLeader Biomedical Co., Ltd. at about 3.2B TWD (market capitalisation, as of Nov 9, 2026). Per share that is 70.60 TWD; our models calculate a fair value of 55.88 TWD per share.
What do the bullish and bearish scenarios say about 7713?
Our models span a range for WeLeader Biomedical Co., Ltd.: cautious scenario 31.01 TWD, base 55.88 TWD, optimistic 87.75 TWD per share (as of Nov 9, 2026, price 70.60 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 7713?
WeLeader Biomedical Co., Ltd. trades at a price-to-earnings ratio of 14.0 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 55.88 TWD is built from several models across several years. Other multiples: P/B 2.6, P/S 2.7, EV/EBITDA 10.2.
How solid is the balance sheet of WeLeader Biomedical Co., Ltd. (7713)?
Balance-sheet figures for WeLeader Biomedical Co., Ltd. (as of Nov 9, 2026): return on equity 21.8%, debt of 0.39 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is 7713 from its 52-week high?
WeLeader Biomedical Co., Ltd. trades at 70.60 TWD, about 6% below its 52-week high of 75.00 TWD and 8% above the low of 65.43 TWD (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 55.88 TWD is for.
Which stocks are comparable to WeLeader Biomedical Co., Ltd.?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is WeLeader Biomedical Co., Ltd. stock attractive at the current price?
The data as of Nov 9, 2026: price 70.60 TWD, calculated fair value 55.88 TWD (−21%), Quality Score 48/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 7713 calculated?
We run WeLeader Biomedical Co., Ltd. through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 55.88 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.7% above its aggregate fair value. WeLeader Biomedical Co., Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of WeLeader Biomedical Co., Ltd. (7713)?
The closing price on Nov 9, 2026 was 70.60 TWD. Our model-based fair value is 55.88 TWD, about 21% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with WeLeader Biomedical Co., Ltd. right now?
Weak quality (48/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide (31.01 TWD to 87.75 TWD). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Key figures of WeLeader Biomedical Co., Ltd.
How large is the market capitalisation of WeLeader Biomedical Co., Ltd. (7713)?
The market capitalisation of WeLeader Biomedical Co., Ltd. is 3.2B TWD (≈ $97.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of WeLeader Biomedical Co., Ltd. (7713)?
The price-to-sales ratio of WeLeader Biomedical Co., Ltd. is 2.66 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of WeLeader Biomedical Co., Ltd. (7713)?
Earnings per share at WeLeader Biomedical Co., Ltd. are 5.05 TWD (price ÷ EPS = P/E 14.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of WeLeader Biomedical Co., Ltd. (7713)?
The dividend yield of WeLeader Biomedical Co., Ltd. is 5.8% (payout 81.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of WeLeader Biomedical Co., Ltd. (7713)?
The net margin of WeLeader Biomedical Co., Ltd. is 20.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of WeLeader Biomedical Co., Ltd. (7713)?
The return on equity (ROE) of WeLeader Biomedical Co., Ltd. is 21.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of WeLeader Biomedical Co., Ltd. (7713)?
On an EBIT basis the return on assets of WeLeader Biomedical Co., Ltd. is 12.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of WeLeader Biomedical Co., Ltd. (7713)?
The operating margin of WeLeader Biomedical Co., Ltd. is 27.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at WeLeader Biomedical Co., Ltd. (7713)?
Revenue at WeLeader Biomedical Co., Ltd. is growing +24.2% versus a year earlier (3y avg +2.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at WeLeader Biomedical Co., Ltd. (7713)?
Earnings per share at WeLeader Biomedical Co., Ltd. are growing +39.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does WeLeader Biomedical Co., Ltd. (7713) carry?
The net debt of WeLeader Biomedical Co., Ltd. is 262M TWD (fiscal year 2025, ≈ 2.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch WeLeader Biomedical Co., Ltd. in the live analysis
One click puts WeLeader Biomedical Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 9, 2026